The Role of MicroRNA in Contrast-Induced Nephropathy: A Scoping Review and Meta-Analysis
Table 1
Summary of the included studies.
Authors
Animal model
Human validation
Contrast
Control
CIN definition
Validated miRNA
Funding
Cheng 2019
Sprague-Dawley rats (250-300 g)
N/A
Iohexol
Saline
N/A
N/A
National Natural Science Foundation of China, National Science and Technology Support Program of China
Liu Y 2019
Sprague-Dawley rats (200-220 g)
N/A
Nonionic low-osmolar iodic contrast medium iopromide
Saline
N/A
N/A
National Science Foundation for Young Scientists of China, National Science Foundation of China, Science and Technology Planning Project of Guangdong Province, Guangdong Provincial Medical Research Fund Project, Guangdong Provincial People’s Hospital Clinical Transformation Research Project
Liu B 2019
Sprague-Dawley rats (200-220 g)
N/A
Isotonic CM iodixanol
Saline
Increase in serum Scr or Cys C concentration of 25% above baseline within 48 to 72 h after contrast administration
N/A
National Science Foundation for Young Scientists of China, National Science Foundation of China, Science and Technology Planning Project of Guangdong Province, Guangdong Provincial Medical Research Fund Project, Guangdong Provincial Research Fund for Science and Technology, Guangdong Provincial People’s Hospital Clinical Research Project
Wang 2019
Sprague-Dawley rats (300-400 g)
N/A
Nonionic monomeric low-osmolarity CM iopromide
Saline
N/A
N/A
The Natural Science Foundation of Fujian province, The Outstanding Youth Science Fund Project of No. 900 Hospital of Chinese PLA, The Health Care Project of Chinese PLA
Sun 2016
Sprague-Dawley male rats (250-300 g)
CAG/PCI patients
Nonionic, low-osmolar CM, iohexol
Saline
Absolute increase in mg/dL or relative Increase in or over baseline 24-48 hours after CM administration
miR-188, miR-30a, and miR-30e
National Natural Science Foundation of China, Shanghai Municipal Commission of Health and Family Planning, Shanghai Jiaotong University
Gutierrez-Escolano 2015
Sprague-Dawley male rats (220-300 g)
PCI patients
Type unknown
PBS
Absolute increase in SCr to ≥0.5 mg/dL or relative Increase in over baseline 24-48 hours after CM administration
